Wednesday’s Highlights at Noon: ImmunoCellular Therapeutics (IMUC), Titan Pharmaceuticals (TTNP), Inovio Pharmaceuticals (INO), Halcon Resources (HK), Ensco Rowan plc (ESV)

By Carrie Williams

So far Wednesday, June 26, NASDAQ is down -0.84% and the S&P is down -0.54%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; ImmunoCellular Therapeutics (IMUCResearch Report), Titan Pharmaceuticals (TTNPResearch Report), Inovio Pharmaceuticals (INOResearch Report), Halcon Resources (HKResearch Report) and Ensco Rowan plc (ESVResearch Report).

ImmunoCellular Therapeutics is down -14.87% in midday trading to $0.02. Shares opened today at $0.02. The company has a 52-week low of $0.01 and a 52-week high of $0.00.

Titan Pharmaceuticals is down -14.2% in midday trading to $1.39. Shares opened today at $1.62. The company has a 52-week low of $1.03 and a 52-week high of $0.00.

Inovio Pharmaceuticals is up 13.64% in midday trading to $3.00. Shares opened today at $2.64. The company has a 52-week low of $2.15 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $11.00, marking a 316.67% potential upside from current levels. In a report issued on June 11, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on INO, with a price target of $13, which implies an upside of 392% from current levels. In the last 30 days, insiders have sold $5M worth of INO shares and purchased $50K worth of INO shares. Over the last 3 months, the insider sentiment on Inovio Pharmaceuticals has been negative based on 22 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Halcon Resources is up 12.58% in midday trading to $0.18. Shares opened today at $0.16. The company has a 52-week low of $0.16 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $1.00, marking a 516.90% potential upside from current levels. In a report issued on May 13, Imperial analyst Jason Wangler maintained a Hold rating on HK, with a price target of $1, which implies an upside of 517% from current levels.

Ensco Rowan plc is up 9.74% in midday trading to $8.56. Shares opened today at $7.80. The company has a 52-week low of $6.54 and a 52-week high of $0.00. On the Street’s front, the average 12-month analyst price target for the stock is $16.63, marking a 113.21% potential upside from current levels. In a report issued on June 10, Merrill Lynch analyst Chase Mulvehill resumed coverage with a Sell rating on ESV and a price target of $7, which reflects a potential downside of -10% from last closing price. Separately, on May 17, RBC’s Kurt Hallead initiated coverage with a Buy rating on the stock and has a price target of $15. In the last 30 days, insiders have sold $26.91K worth of ESV shares and purchased $128.9K worth of ESV shares.

Trending Stocks Based on Insider Activity >>